Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman,

Slides:



Advertisements
Similar presentations
Lipids, Lipoproteins and Aging
Advertisements

Lipoprotein Structure, Function, and Metabolism
Lipoprotein Metabolism And Disorders
Lipoproteins Function: Transport of fat soluble substances
LIPOPROTEIN METABOLISM
COMPOSITION OF LIPIDS Lipoproteins Apolipoproteins Lipoproteins Apolipoproteins Cholesterol Protein Triglyceride Phospholipid.
Friend or Foe? High HDL Cholesterol. High Density Lipoprotein Origin: liver Content: 18-25% TC content 45-55% Protein 2-7% TG 20-30% Phospholipids Density:
Lipoprotein Structures, Function and Metabolism (1)
Dr Abdul Lateef Assistant professor Dept of Biochemistry.
Lipid Homeostasis and Transport CH353 February 12, 2008.
1 Lipoproteins Seminar No A.1 - Lipids of Blood Plasma LipidPlasma concentration Cholesterol (C+CE)* Phospholipids Triacylglycerols Free fatty acids.
Lipoprotein Structure and Function LP core Triglycerides Cholesterol esters LP surface Phospholipids Proteins Cholesterol Are conjugated proteins, composed.
Overview Lipoprotein metabolism Digestive lipid metabolism
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Discovery of a New Role of Human Resistin in Hepatocyte.
Copyright © 2016 McGraw-Hill Education. All rights reserved.
Lipids in the diet are hydrolyzed in the small intestine, and the resultant fatty acids and monoglycerides are repackaged with apoB-48 into TG-enriched.
Lipoprotein Structure, Function, and Metabolism
Cholesterol metabolism
Hyperlipidemias.
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
Schematic overview of the role of LCAT in lipoprotein metabolism
LIPOPROTEINS A to Z.
Plasma Lipid Transport Role of HDL
THE MANY FUNCTIONS OF INSULIN IN LIPID METABOLISM
Dr. Eman Shaat Professor of Medical Biochemistry and Molecular Biology
HDL and Atherosclerosis
Paul Durrington  Atherosclerosis Supplements 
Figure 6 Cholesterol metabolism in obesity-related glomerulopathy
Review of Cholesterol and Lipoproteins
Figure 2 Hepatic action of functional foods and supplements
Dyslipidemia in chronic kidney disease: Causes and consequences
Cholesterol and Lipoproteins
Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.
My Approach to the Patient With Familial Hypercholesterolemia
Nat. Rev. Cardiol. doi: /nrcardio
Figure 4 Acute-phase HDL
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia  Joep C. Defesche, PhD,
A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the.
Advanced Nutrition Lipids 5 MargiAnne Isaia, MD MPH.
HCV and the hepatic lipid pathway as a potential treatment target
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study) 
Volume 7, Issue 5, Pages (May 2008)
Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis  Robert Wolk, MD, PhD, DSc, Ehrin J.
HDL and Atherosclerosis
Jonathan C. Cohen, PhD  Journal of Clinical Lipidology 
Eveline Oestreicher Stock, MD, Christine T
Dual Role of Circulating Angiopoietin-Like 4 (ANGPTL4) in Promoting Hypertriglyceridemia and Lowering Proteinuria in Nephrotic Syndrome  Nosratola D.
New Therapeutic Approaches to the Treatment of Dyslipidemia
Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National.
Guido T. Bommer, Ormond A. MacDougald  Cell Metabolism 
Lipoproteins.
Copyright © 2016 Elsevier Inc. All rights reserved.
Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate
Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease  Guenther Silbernagel, MD, Iris Baumgartner, MD, Christoph Wanner, MD,
Daniel J. Rader, Ellen Puré  Cell Metabolism 
Volume 7, Issue 5, Pages (May 2008)
The genetics of alcohol dependence and alcohol-related liver disease
Figure 1 The major pathways of lipid metabolism
New insights into lipid metabolism in the nephrotic syndrome
Influence of low-glucose peritoneal dialysis on serum lipids and apolipoproteins in the IMPENDIA/EDEN trials  Allan D. Sniderman, MD, James A. Sloand,
Daniel J. Rader, Ellen Puré  Cell Metabolism 
Nat. Rev. Nephrol. doi: /nrneph
Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication.
Schematic representation of dyslipidaemia of metabolic syndrome.
Potential Mechanisms of Adverse Outcomes Associated with Torcetrapib
Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis  Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang 
Lipoproteins   Macromolecular complexes in the blood that transport lipids Apolipoproteins   Proteins on the surface of lipoproteins; they play critical.
Reverse cholesterol transport CETP is key in remodeling of HDL
Plasma lipid exchange. Plasma lipid exchange. In the presence of increased concentrations of VLDL in the circulation, cholesteryl ester transfer protein.
Presentation transcript:

Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency  Don P. Wilson, MD, FNLA, Mark Friedman, MD, Sachin Marulkar, MBBS, MPH, Tyler Hamby, PhD, Eric Bruckert, MD  Journal of Clinical Lipidology  Volume 12, Issue 3, Pages 604-614 (May 2018) DOI: 10.1016/j.jacl.2018.02.020 Copyright © 2018 National Lipid Association Terms and Conditions

Figure 1 Percentage change from baseline in lipid and atherogenic biomarkers in LAL-D patients at 20 weeks of treatment. P values determined using the Wilcoxon rank-sum test. Columns show the mean change with standard deviation bars; median values are denoted by asterisks (*). ApoA1, apolipoprotein A1; apoB, apolipoprotein B; LAL-D, lysosomal acid lipase deficiency; LDL-P, low-density lipoprotein particle; NS, not significant. Journal of Clinical Lipidology 2018 12, 604-614DOI: (10.1016/j.jacl.2018.02.020) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 2 Percentage change from baseline at 20 weeks for HDL-C (A) and LDL-C (B). The letter “L” indicates the patients who also received lipid-lowering medication. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Journal of Clinical Lipidology 2018 12, 604-614DOI: (10.1016/j.jacl.2018.02.020) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 3 Lipid metabolism in normal (A) and LAL-D hepatocytes (B). (A) Low-density lipoprotein (LDL) is taken up into the hepatocyte and delivered to the lysosome via the LDL receptor (LDLR). The secreted protein, proprotein convertase subtilisin/kexin type 9 (PCSK9), causes the degradation of LDLR in the lysosome. Triglycerides (TG) and cholesteryl esters (CE) are de-esterified in the lysosome by lysosomal acid lipase (LAL) to form free cholesterol (FC) and free fatty acids (FFA), respectively. Niemann-Pick C1 protein (NPC1) and C2 (NPC2) translocate FC from lysosome to cytoplasm. FC and FFA interact with sterol regulatory element–binding proteins (SREBP) to provide feedback inhibition, which decreases production and intake of cholesterol. FC causes activation of the nuclear liver X receptor (LXR), which increases the efflux of cholesterol via the adenosine triphosphate–binding cassette transporter A1 (ABCA1)–mediated production of nascent high-density lipoprotein (HDL) particles. (B) In the absence of LAL, cytosolic FC and FFA levels are diminished, resulting in an increase in levels of serum LDL, an increase in receptor-mediated LDL cholesterol uptake, and increased synthesis, packaging, and secretion of very-low-density lipoprotein (VLDL), which contributes to LDL levels and a decrease in FC efflux via HDL. In addition, cholesteryl ester transfer protein (CETP) facilitates the removal of CE from HDL and LDL in exchange for TG, which may further reduce serum HDL cholesterol levels. ACAT, acyl-coenzyme A:cholesterol acyltransferase; apoA1, apolipoprotein A1; apoB100, apolipoprotein B100; FA, fatty acids; HEL, hepatic endothelial lipase; HMGCR, hydroxymethylglutaryl-coenzyme A reductase; IDL, intermediate-density lipoprotein; LAL-D, LAL deficiency; LCAT, lecithin-cholesterol acyltransferase; LPL, lipoprotein lipase; MTTP, microsomal triglyceride transfer protein. Adapted from Reiner et al2 (Atherosclerosis. 2014; 235:21–30) and Maciejko33 (Am J Cardiovasc Drugs. 2017; 17:217–231). Journal of Clinical Lipidology 2018 12, 604-614DOI: (10.1016/j.jacl.2018.02.020) Copyright © 2018 National Lipid Association Terms and Conditions

Figure 4 Lipid-lowering medications intended to improve lipid homeostasis in normal hepatocytes (A) may exacerbate the underlying mechanisms of disease in LAL-D (B). (A) Statins inhibit hydroxymethylglutaryl-coenzyme A reductase (HMGCR), disrupting synthesis of free cholesterol (FC). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors prevent degradation of low-density lipoprotein receptor (LDLR). PCSK9 levels may increase as a feedback response to statins. Upregulation of PCSK9 may attenuate the statin-induced reduction in low-density lipoprotein (LDL) cholesterol. Statins may increase apolipoprotein A1 (apoA1) production. (B) Both statins, which disrupt synthesis of FC, and PCSK9 inhibitors, which prevent degradation of LDLR, can markedly increase LDL uptake. Although not proven, increased uptake of LDL may exacerbate hepatic lipid accumulation in LAL-D. Disrupting synthesis of FC with statins may reduce activity of liver X receptor (LXR) and further decrease high-density lipoprotein (HDL) production. ABCA1, adenosine triphosphate–binding cassette transporter A1; ACAT, acyl-coenzyme A:cholesterol acyltransferase; apoB100, apolipoprotein B100; CE, cholesteryl esters; CETP, cholesteryl ester transfer protein; FA, fatty acids; FFA, free fatty acids; HEL, hepatic endothelial lipase; IDL, intermediate-density lipoprotein; LAL, lysosomal acid lipase; LAL-D, lysosomal acid lipase deficiency; LCAT, lecithin-cholesterol acyltransferase; LPL, lipoprotein lipase; MTTP, microsomal triglyceride transfer protein; Niemann-Pick C1 protein (NPC1) and C2 (NPC2); SREBP, sterol regulatory element–binding proteins; TG, triglycerides; VLDL, very-low-density lipoprotein. Adapted from Reiner et al2 (Atherosclerosis. 2014; 235:21–30) and Maciejko33 (Am J Cardiovasc Drugs. 2017; 17:217–231). Journal of Clinical Lipidology 2018 12, 604-614DOI: (10.1016/j.jacl.2018.02.020) Copyright © 2018 National Lipid Association Terms and Conditions